Not to be administered IV. Not for diabetic ketoacidosis. Patients w/ significant stenoses of coronary arteries or blood vessels supplying the brain, proliferative retinopathy; patients in whom glycaemic control is markedly improved, hypoglycaemia develops gradually & autonomic neuropathy is present, after transfer from animal to human insulin, long history of diabetes, suffering from psychiatric illness, receiving concurrent treatment w/ certain other medicinal products; change in inj area, improved insulin sensitivity; unaccustomed, increased or prolonged physical activity; intercurrent illness, inadequate food intake, missed meals, alcohol consumption, certain uncompensated endocrine disorders (eg, hypothyroidism & anterior pituitary or adrenocortical insufficiency); switching between & from other insulins. Formation of insulin Ab. Risk of developing lipodystrophy & cutaneous amyloidosis; monitor blood glucose after change in inj site. Not to be mixed w/ any other insulin or diluted. Combination w/ pioglitazone. May affect ability to drive & use machines. Renal or hepatic impairment. Pregnancy & lactation. Childn <2 yr. Elderly ≥65 yr.
Sign Out
